Performance of the resolute zotarolimus-eluting stent in small vessels

Catheterization and Cardiovascular Interventions

Volumn 84, Issue 1, 2014, Pages 17-23

  Caputo, Ronald ^a   Leon, Martin ^b   Serruys, Patrick ^c   Neumann, Franz Josef ^d   Yeung, Alan ^e   Windecker, Stephan ^f   Belardi, Jorge A ^g   Silber, Sigmund ^h   Meredith, Ian ⁱ   Widimský, Petr ^j   Saito, Shigeru ^k   Mauri, Laura ^l  

^a St Joseph's Hospital Cardiology Assoc   (United States)

^b CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^c ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^d UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF BERN   (Switzerland)

^g INSTITUTO CARDIOVASCULAR DE BUENOS AIRES   (Argentina)

^h Heart Center at the Isar   (Germany)

ⁱ MONASH UNIVERSITY   (Australia)

^j CHARLES UNIVERSITY   (Czech Republic)

^k SHONAN KAMAKURA GENERAL HOSPITAL   (Japan)

^l BRIGHAM AND WOMEN S HOSPITAL   (United States)

more..

Author keywords

coronary artery disease; diabetes; drug eluting stent; small vessel disease

Indexed keywords

ZOTAROLIMUS; RAPAMYCIN;

ADULT; ADVERSE OUTCOME; ARTICLE; BLOOD VESSEL DIAMETER; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; COMORBIDITY; COMPARATIVE EFFECTIVENESS; CORONARY ARTERY DISEASE; DEVICE SAFETY; DEVICE THERAPY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MICROANGIOPATHY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); ANALOGS AND DERIVATIVES; ANGIOCARDIOGRAPHY; CLINICAL TRIAL; COMPARATIVE STUDY; CORONARY BLOOD VESSEL; MIDDLE AGED; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PROCEDURES; PROSPECTIVE STUDY; PROSTHESIS; RADIOGRAPHY; REGISTER; TIME; TREATMENT OUTCOME;

CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY VESSELS; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; REGISTRIES; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84903546697     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.25485     Document Type: Article

References (24)

1. Kastrati A, Dibra A, Mehilli J, Mayer S, Pinieck S, Pache J, Dirschinger J, Schomig A,. Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents. Circulation 2006; 113: 2293-2300.
2. Mehilli J, Dibra A, Kastrati A, Pache J, Dirschinger J, Schomig A, Intracoronary Drug-Eluting Stenting to Abrogate Restenosis in Small Arteries Study I. Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels. Eur Heart J 2006; 27: 260-266.
3. Tanimoto S, Daemen J, Tsuchida K, Garcia-Garcia HM, de Jaegere P, van Domburg RT, Serruys PW,. Two-year clinical outcome after coronary stenting of small vessels using 2.25-mm sirolimus- and paclitaxel-eluting stents: Insight into the RESEARCH and T-SEARCH registries. Catheter Cardiovasc Interv 2007; 69: 94-103.
4. Airoldi F, Colombo A, Morici N, Latib A, Cosgrave J, Buellesfeld L, Bonizzoni E, Carlino M, Gerckens U, Godino C, Melzi G, Michev I, Montorfano M, Sangiorgi GM, Qasim A, Chieffo A, Briguori C, Grube E,. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 2007; 116: 745-754.
5. Gao R, Abizaid A, Banning A, Bartorelli AL, Dzavik V, Ellis S, Jeong MH, Legrand V, Spaulding C, Urban P,. One-year outcome of small-vessel disease treated with sirolimus-eluting stents: A subgroup analysis of the e-SELECT registry. J Interv Cardiol 2013; 26: 163-172.
6. Habara S, Mitsudo K, Goto T, Kadota K, Fujii S, Yamamoto H, Kato H, Takenaka S, Fuku Y, Hosogi S, Hirono A, Yamamoto K, Tanaka H, Hasegawa D, Nakamura Y, Tasaka H, Otsuru S, Okamoto Y, Yamada C, Miyamoto M, Inoue K,. The impact of lesion length and vessel size on outcomes after sirolimus-eluting stent implantation for in-stent restenosis. Heart 2008; 94: 1162-1165.
7. Hsieh IC, Chien CC, Chang HJ, Chern MS, Hung KC, Lin FC, Wu D,. Acute and long-term outcomes of stenting in coronary vessel > 3.0 mm, 3.0-2.5 mm, and < 2.5 mm. Catheter Cardiovasc Interv 2001; 53: 314-322.
8. Suselbeck T, Latsch A, Siri H, Gonska B, Poerner T, Pfleger S, Schumacher B, Borggrefe M, Haase KK,. Role of vessel size as a predictor for the occurrence of in-stent restenosis in patients with diabetes mellitus. Am J Cardiol 2001; 88: 243-247.
9. Mazeika P, Prasad N, Bui S, Seidelin PH,. Predictors of angiographic restenosis after coronary intervention in patients with diabetes mellitus. Am Heart J 2003; 145: 1013-1021.
10. Biondi-Zoccai G, Moretti C, Abbate A, Sheiban I,. Percutaneous coronary intervention for small vessel coronary artery disease. Cardiovasc Revasc Med 2010; 11: 189-198.
11. Meredith IT, Worthley S, Whitbourn R, Walters DL, McClean D, Horrigan M, Popma JJ, Cutlip DE, DePaoli A, Negoita M, Fitzgerald PJ,. Clinical and angiographic results with the next-generation resolute stent system: A prospective, multicenter, first-in-human trial. JACC Cardiovasc Interv 2009; 2: 977-985.
12. Meredith IT, Worthley SG, Whitbourn R, Walters D, McClean D, Ormiston J, Horrigan M, Wilkins GT, Hendriks R, Matsis P, Muller D, Cutlip DE,. Long-term clinical outcomes with the next-generation Resolute stent system: A report of the two-year follow-up from the RESOLUTE clinical trial. EuroIntervention 2010; 5: 692-697.
13. Mauri L, Leon MB, Yeung AC, Negoita M, Keyes MJ, Massaro JM,. Rationale and design of the clinical evaluation of the Resolute zotarolimus-eluting coronary stent system in the treatment of de novo lesions in native coronary arteries (the RESOLUTE US clinical trial). Am Heart J 2011; 161: 807-814.
14. Yeung AC, Leon MB, Jain A, Tolleson TR, Spriggs DJ, Mc Laurin BT, Popma JJ, Fitzgerald PJ, Cutlip DE, Massaro JM, Mauri L,. Clinical evaluation of the Resolute zotarolimus-eluting coronary stent system in the treatment of de novo lesions in native coronary arteries: The RESOLUTE US clinical trial. J Am Coll Cardiol 2011; 57: 1778-1783.
15. Serruys PW, Silber S, Garg S, van Geuns RJ, Richardt G, Buszman PE, Kelbaek H, van Boven AJ, Hofma SH, Linke A, Klauss V, Wijns W, Macaya C, Garot P, DiMario C, Manoharan G, Kornowski R, Ischinger T, Bartorelli A, Ronden J, Bressers M, Gobbens P, Negoita M, van Leeuwen F, Windecker S,. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med 2010; 363: 136-146.
16. Silber S, Windecker S, Vranckx P, Serruys PW,. Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-Year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. Lancet 2011; 377: 1241-1247.
17. Neumann FJ, Widimsky P, Belardi JA,. One-year outcomes of patients with the zotarolimus-eluting coronary stent: RESOLUTE International Registry. EuroIntervention 2012; 7: 1181-1188.
18. Silber S, Serruys PW, Leon MB, Meredith IT, Windecker S, Neumann FJ, Belardi J, Widimsky P, Massaro J, Novack V, Yeung AC, Saito S, Mauri L,. Clinical outcome of patients with and without diabetes mellitus after percutaneous coronary intervention with the resolute zotarolimus-eluting stent: 2-Year results from the prospectively pooled analysis of the international global RESOLUTE Program. J Am Coll Cardiol 2013; 6: 357-368.
19. Udipi K, Chen M, Cheng P, Jiang K, Judd D, Caceres A, Melder RJ, Wilcox JN,. Development of a novel biocompatible polymer system for extended drug release in a next-generation drug-eluting stent. J Biomed Mater Res A 2008; 85: 1064-1071.
20. Udipi K, Melder RJ, Chen M, Cheng P, Hezi-Yamit A, Sullivan C, Wong J, Wilcox J,. The next generation Endeavor Resolute Stent: Role of the BioLinx Polymer System. EuroIntervention 2007; 3: 137-139.
21. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW,. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007; 115: 2344-2351.
22. Claessen BE, Smits PC, Kereiakes DJ, Parise H, Fahy M, Kedhi E, Serruys PW, Lansky AJ, Cristea E, Sudhir K, Sood P, Simonton CA, Stone GW,. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) randomized trials. JACC Cardiovasc Interv 2011; 4: 1209-1215.
23. Hermiller JB, Fergus T, Pierson W, Su X, Sood P, Sudhir K, Stone GW,. Clinical and angiographic comparison of everolimus-eluting and paclitaxel-eluting stents in small coronary arteries: A post hoc analysis of the SPIRIT III randomized trial. Am Heart J 2009; 158: 1005-1010.
24. Wykrzykowska JJ, Serruys PW, Onuma Y, de Vries T, van Es GA, Buszman P, Linke A, Ischinger T, Klauss V, Corti R, Eberli F, Wijns W, Morice MC, di Mario C, van Geuns RJ, Juni P, Windecker S,. Impact of vessel size on angiographic and clinical outcomes of revascularization with biolimus-eluting stent with biodegradable polymer and sirolimus-eluting stent with durable polymer the LEADERS trial substudy. JACC Cardiovasc Interv 2009; 2: 861-870.